Catecholamine-resistant shock is not uncommon in intensive care. Bolus dose terlipressin (a vasopressin analogue) has been used successfully in this setting allowing cessation of other vasopressor agents. The relative vasopressin deficiency in combination with the restoration of the vascular tone (by blocking adenosine triphosphate potassiumsensitive channels) by exogenous vasopressin may be the explanation of these beneficial effects. We describe a case report where the use of a continuous terlipressin infusion was associated with a dramatic improvement. To our knowledge there have been no previous reports of the use of terlipressin by continuous infusion for the treatment of catecholamine-resistant shock.
Catecholamine-resistant shock is common in intensive care and the use of vasopressin in this setting has been reported in a number of studies [1] [2] [3] . The use of terlipressin, a synthetic analogue of vasopressin, given via intravenous bolus injection, however, has only been reported recently in patients with septic shock 4 . We present a patient with refractory shock where continuous terlipressin infusion resulted in a dramatic decrease in catecholamine requirements. To our knowledge there have been no previous reports of the use of terlipressin by continous infusion for the treatment of catecholamine-resistant shock.
CASE REPORT
A 56-year-old Caucasian male sustained an inhospital ventricular fibrillation arrest on day four of an admission for atrial fibrillation secondary to acute myocardial infarction. This was on a background of ten years of poorly controlled type II diabetes mellitus, hypercholesterolaemia, hypertension, mild chronic airways disease, 80 pack/year smoking history, alcohol 60 g/day and past melioid pneumonia.
Regular medication included Mixtard 30/70 (neutral insulin 30%, isophane insulin 70%) 32 units mane and 20 units nocte, salbutamol 100 µg metered dose inhaler and an unknown antihypertensive agent.
He initially presented with mild left-sided chest discomfort for four days, dyspnoea, general malaise and symptoms suggesting a concurrent mild viral infection. Physical examination showed a blood pressure of 100/74 mmHg, an irregular pulse of 120-160 bpm and temperature 37.3°C. Auscultation demonstrated scattered wheeze in both fields and dual heart sounds. The abdomen was soft and non-tender and neurological examination was unremarkable. An ECG demonstrated atrial fibrillation with a rapid ventricular response and a right bundle branch block, but no acute ischaemic ECG changes were identified. He was commenced on low-molecular weight heparin and an amiodarone infusion which successfully reverted his acute atrial fibrillation. Cardiology review of subsequent ECGs and cardiac enzymes demonstrated a missed posterior myocardial infarction. Troponin I was 275 U/l (normal <0.3 U/l) and creatine kinase 917 ug/l (normal <240 ug/l). Thyroid function tests were normal with free T4 14.8 pmol/l (normal 10.0-24.0 pmol/l) and thyroid stimulating hormone (TSH) 2.74 mU/l (normal 0.50-5.00 mU/l). During his monitored period in the Emergency Department he was stable and pain-free. He was subsequently transferred to the coronary care unit for monitoring, and after three days discharged to an unmonitored ward bed.
On day four the patient was found unconscious on the floor shortly after finishing his midday meal. He was found to be in pulseless ventricular fibrillation. Sinus rhythm was re-established following one defibrillation cycle (DC 200J-200J-360J) and intravenous adrenaline 1 mg. He was intubated and cardiopulmonary resuscitation was continued for three minutes and a further dose of adrenaline 1 mg given before cardiac output was re-established. Upon retrieval to the ICU he was sedated with morphine and midazolam (5 mg/h), commenced on pressurecontrolled ventilation (IP 20 cm H 2 O, PEEP 10 cm H 2 O, FiO 2 100%), loaded with intravenous amiodarone 300 mg and commenced on an adrenaline infusion to maintain a mean arterial pressure above 70 mmHg. Within the first hour of admission, an infusion of 1.0 µg/kg/min adrenaline was required to achieve this mean arterial pressure (MAP) ( Figure  1 ). Arterial blood gas analysis showed pH 7.24, PO 2 61 mmHg [8.1 kPa], PCO 2 53 mmHg [7 kPa] and HCO 3 -22 mmol/l on 100% oxygen. Chest X-ray showed complete shadowing of his left lower lobe suggesting bronchial obstruction. Bronchoscopy identified and removed food pieces obstructing the left lower lobe bronchus, with dramatic improvement in ventilation and subsequent chest X-ray images. Ticarcillin and clavulanic acid (Timentin ® , 3.1 g four times daily) and gentamicin (320 mg as per drug levels) were subsequently commenced for aspiration pneumonia and continued throughout the admission. Transthoracic echocardiography performed at this time demonstrated akinetic anterior, posterior and apical walls, and consequent severely limited left ventricular function.
Within the first 24 hours of his ICU admission he experienced three arrests with pulseless ventricular tachycardia that were successfully defibrillated with a minimal pulseless period. At the end of the first 24 hours in ICU the adrenaline infusion was running at 1 µg/kg/min with a MAP of 55 mmHg. A pulmonary artery catheter was placed with the results as shown in Table 1 protein of 188 mg/l and white blood cell count of 23.0x10 9 /l suggestive for septic shock as a result of an aspiration pneumonia. At 29 hours and due to the low systemic vascular resistance (SVR), adrenaline was replaced with noradrenaline at a dose of 1 µg/kg/min. This produced only a small increase in the SVR to 492 dyn/s/cm 5 and was only able to maintain a MAP of 65 mmHg. Addition of a dobutamine infusion produced no improvement and was ceased after two hours. Continuous veno-venous haemofiltration was commenced for acute renal failure resulting from persistent hypotension, and was continued until day 10.
Due to catecholamine-resistant shock, we decided to start a vasopressin infusion. However, due to vasopressin source problems an infusion of terlipressin instead was commenced at 500 µg/h. This produced an immediate increase in the MAP to 110 mmHg within 10 minutes and the SVR to over 1000 dyn/s/cm 5 , allowing the noradrenaline to be gradually weaned ( Figure 1 ).
Shortly after this improvement hydrocortisone 100 mg 6 hourly was also commenced pending the result of a short Synacthen test that was subsequently negative. Thyroid function tests showed a euthyroid sick syndrome with free T4 8.0 pmol/l (normal 10.0-24.0 pmol/l) and TSH 0.10 mU/l (normal 0.50-5.00 mU/l).
After six hours the terlipressin infusion was reduced to 250 µg/h, at which time the noradrenaline had been decreased by two thirds. The terlipressin was successfully ceased after 18 hours, at which time dobutamine was restarted with an increase in cardiac output from 4.9 to 7.6 l/min. A repeat transthoracic echocardiogram showed persisting poor left ven-tricular function with slightly improved basal anteroseptal contraction. Dobutamine was successfully ceased after 35 hours and the noradrenaline continued at low doses (between 0.01 to 0.1 µg/kg/min) for a further five days.
The patient was extubated on day nine and discharged from the ICU on day eleven of his admission. He was neurologically intact with only mild renal impairment which resolved before hospital discharge. The only identifiable direct adverse effect of the terlipressin infusion was bilaterally reduced toe and forefoot perfusion that slowly resolved during the following week with no long-term sequelae. A subsequent coronary angiogram demonstrated triple-vessel disease and left ventricular dysfunction (ejection fraction less than 30%) for which he was transferred for angioplasty, coronary stenting and electrophysiological studies.
DISCUSSION
Terlipressin (Glypressin ® ), a long-acting vasopressin analogue, has been successfully used in the control of variceal 5,6 , wound 7,8 , urinary 9 and uterine haemorrhage 10 , and has promising benefits in the management of hepatorenal syndrome 11 . However there have been only two reports 12, 4 of the use of terlipressin in refractory hypotension despite its known vasopressor effects. In both of these reports terlipressin boluses were used. There has been no report of the use of a terlipressin infusion in such a setting.
Vasopressin is being increasingly used by infusion (0.01 to 0.04 U/min) as treatment for catecholamineresistant hypotension. Landry and colleagues found that vasopressin deficiency contributes to hypoten- sion in septic shock and that exogenous vasopressin may correct hypotension allowing the weaning and sometimes cessation of other pressors 1, 2 . As well as a direct vasoconstricting effect, vasopressin may also enhance the pressor response to catecholamines by blocking the potassium-sensitive adenosine triphosphate channels in a dose-dependent manner subsequently restoring vascular tone 1, 3 . Cessation of vasopressin however may often lead to rebound hypotension 2,3 requiring vasopressin infusions to be ceased slowly over several days. Holmes et al 13 postulated that the use of a low-dose vasopressin (0.04 U/min) in patients with severe septic shock potentially avoids renal, mesenteric, pulmonary, and coronary ischaemia, as well as the hypercoagulable effects of high-dose vasopressin. The potential benefits of low-dose vasopressin include restoration of vasomotor tone and preservation of renal blood flow and urine output 3 . High-dose vasopressin may compromise organ blood distribution and tissue perfusion due to excessive vasoconstriction: reduction in splanchnic blood flow 14 , aggravation of gastric lesions in stressed rats 15 or reduction in gastric mucosal hyperaemia 16 in patients with cirrhosis.
There is also some concern that vasopressin may lead to a reduction in cardiac output 1,2 and hence be contraindicated in cardiogenic shock. Other studies have not confirmed this 3 and postulate that the observation may in fact represent baroreflex activation. Tsuneyoshi and coworkers did not observe decreased in cardiac output during vasopressin infusion 3 . Except for a coronary constricting effect, which could lead to ischaemic cardiac dysfunction, vasopressin is known to have little direct effect on heart function 17 .
Terlipressin is a synthetic triglycyl-lysine derivative of vasopressin and a prodrug of lypressin (lysine-8vasopressin). It possesses a longer duration of action (2-10 hours) than both lypressin and vasopressin 18 . Terlipressin has an alpha half-life of 8 to 9 minutes and a beta half-life of 51 to 66 minutes. The cardiovascular effects are comparable to those of vasopressin, producing profound systemic vasoconstriction. The comparative vasopressor effects of vasopressin and terlipressin have not yet been quantified.
Although not widely used, the vasopressor effect of terlipressin has been previously reported. Rittig et al 19 demonstrated the beneficial vasopressor effects of terlipressin in patients with orthostatic hypotension due to Parkinson's disease 19 . Eyraud et al successfully managed intraoperative hypotension with 1 mg terlipressin boluses in 51 vascular surgery patients who were chronically treated with ACE inhibitors or ATIIreceptor antagonists 12 . Most recently, O'Brien, Clapp and Singer demonstrated the use of a single bolus of terlipressin in a series of norepinephrine-resistant patients with septic shock 4. In all eight patients an intravenous bolus of terlipressin 1-2 mg produced an increase in mean arterial pressure sustained over 24 hours, with four patients surviving to hospital discharge. There were no harmful side-effects such as splanchnic and myocardial ischaemia or worsening metabolic acidosis.
Other studies however, have shown that boluses of terlipressin in refractory shock may lead to a rise in gastric PCO 2 gap suggesting gut microvascular dysfunction 20 . The clinical importance of this finding in sepsis is unclear. Asfar et al have shown that low-dose terlipressin in fluid-challenged endotoxic rats significantly increased ileal microcirculation and had no detrimental effect on mesenteric blood flow in comparison with hypodynamic endotoxic rats. In the fluid resuscitated rats, low-dose terlipressin did not result in a decrease in the indexed aortic blood flow 21 .
In our case, a terlipressin infusion produced a measurable and impressive improvement in haemodynamic parameters. Although this patient's survival is owed to a variety of interventions, the institution of a terlipressin infusion produced a dramatic clinical and physiological improvement at a time when conventional therapies appeared exhausted. This patient's shock was initially cardiogenic in nature due to severe left ventricular dysfunction following his acute myocardial infarct, and subsequently septic due to aspiration pneumonia sustained at the time of his arrest and subsequent systemic inflammatory response syndrome. His improvement suggests that terlipressin may offer benefits in refractory shock, even though the dramatic increase in SVR should be detrimental in the setting of a failing left ventricle.
Terlipressin may offer advantages over vasopressin due to its longer duration of action and thus less dramatic change in pressor effect as infusions are altered or ceased, however a precise understanding of the degree of pressor effect of terlipressin in comparison with vasopressin is still unclear. We used a rather large dose of 500 micrograms/h of terlipressin for six hours followed by a reduced dose of 250 micrograms/h for a further twelve hours. The total dose given in our patient was 6 mg/18h which is comparable with the dose used for bleeding oesophageal varices. The potential benefit of this novel vasopressin-analogue in the setting of catecholamineresistant hypotension merits further investigation.
